Cargando…
A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study
Background: This study was a multicenter, randomized, double-blinded, placebo-controlled phase III clinical trial to investigate the efficacy and safety of an olmesartan/amlodipine single pill plus rosuvastatin combination treatment for patients with concomitant hypertension and dyslipidemia. Method...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779537/ https://www.ncbi.nlm.nih.gov/pubmed/35054044 http://dx.doi.org/10.3390/jcm11020350 |
_version_ | 1784637601501675520 |
---|---|
author | Jo, Sang-Ho Kang, Seok Min Yoo, Byung Su Lee, Young Soo Youn, Ho Joong Min, Kyungwan Yu, Jae Myung Yoon, Hyun Ju Kim, Woo Shik Kim, Gee Hee Park, Jae Hyoung Kim, Seok Yeon Kim, Cheol Ho |
author_facet | Jo, Sang-Ho Kang, Seok Min Yoo, Byung Su Lee, Young Soo Youn, Ho Joong Min, Kyungwan Yu, Jae Myung Yoon, Hyun Ju Kim, Woo Shik Kim, Gee Hee Park, Jae Hyoung Kim, Seok Yeon Kim, Cheol Ho |
author_sort | Jo, Sang-Ho |
collection | PubMed |
description | Background: This study was a multicenter, randomized, double-blinded, placebo-controlled phase III clinical trial to investigate the efficacy and safety of an olmesartan/amlodipine single pill plus rosuvastatin combination treatment for patients with concomitant hypertension and dyslipidemia. Methods: Patients with both hypertension and dyslipidemia aged 20–80 were enrolled from 36 tertiary hospitals in Korea from January 2017 to April 2018. Patients were randomized to three groups in a 1:1:0.5 ratio, olmesartan/amlodipine single pill plus rosuvastatin (olme/amlo/rosu) or olmesartan plus rosuvastatin (olme/rosu) or olmesartan/amlodipine single pill (olme/amlo) combination. The primary endpoints were change of sitting systolic blood pressure (sitSBP) from baseline in the olme/amlo/rosu vs. olme/rosu groups and the percentage change of low-density lipoprotein cholesterol (LDL-C) from baseline in the olme/amlo/rosu vs. olme/amlo groups after 8 weeks of treatment. Results: A total of 265 patients were randomized, 106 to olme/amlo/rosu, 106 to olme/rosu and 53 to olme/amlo groups. Baseline characteristics among the three groups did not differ. The mean sitSBP change was significantly larger in the olme/amlo/rosu group with −24.30 ± 12.62 mmHg (from 153.58 ± 10.90 to 129.28 ± 13.58) as compared to the olme/rosu group, −9.72 ± 16.27 mmHg (from 153.71 ± 11.10 to 144.00 ± 18.44 mmHg). The difference in change of sitSBP between the two groups was −14.62± 1.98 mmHg with significance (95% CI −18.51 to −10.73, p < 0.0001). The mean LDL-C reduced significantly in the olme/amlo/rosu group, −52.31 ± 16.63% (from 154.52 ± 30.84 to 72.72 ± 26.08 mg/dL) as compared to the olme/amlo group with no change, −2.98 ± 16.16% (from 160.42 ± 32.05 to 153.81 ± 31.57 mg/dL). Significant difference in change was found in LDL-C between the two groups with −50.10 ± 2.73% (95% CI −55.49 to −44.71, p < 0.0001). Total adverse drug reaction rates were 10.48%, 5.66% and 3.7% in the olme/amlo/rosu, olme/rosu and olme/amlo groups, respectively with no statistical significance among the three groups. Serious adverse drug reactions did not occur. Conclusions: Olmesartan/amlodipine single pill plus rosuvastatin combination treatment for patients with both hypertension and dyslipidemia is effective and safe as compared to either olmesartan plus rosuvastatin or olmesartan plus amlodipine treatment. |
format | Online Article Text |
id | pubmed-8779537 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87795372022-01-22 A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study Jo, Sang-Ho Kang, Seok Min Yoo, Byung Su Lee, Young Soo Youn, Ho Joong Min, Kyungwan Yu, Jae Myung Yoon, Hyun Ju Kim, Woo Shik Kim, Gee Hee Park, Jae Hyoung Kim, Seok Yeon Kim, Cheol Ho J Clin Med Article Background: This study was a multicenter, randomized, double-blinded, placebo-controlled phase III clinical trial to investigate the efficacy and safety of an olmesartan/amlodipine single pill plus rosuvastatin combination treatment for patients with concomitant hypertension and dyslipidemia. Methods: Patients with both hypertension and dyslipidemia aged 20–80 were enrolled from 36 tertiary hospitals in Korea from January 2017 to April 2018. Patients were randomized to three groups in a 1:1:0.5 ratio, olmesartan/amlodipine single pill plus rosuvastatin (olme/amlo/rosu) or olmesartan plus rosuvastatin (olme/rosu) or olmesartan/amlodipine single pill (olme/amlo) combination. The primary endpoints were change of sitting systolic blood pressure (sitSBP) from baseline in the olme/amlo/rosu vs. olme/rosu groups and the percentage change of low-density lipoprotein cholesterol (LDL-C) from baseline in the olme/amlo/rosu vs. olme/amlo groups after 8 weeks of treatment. Results: A total of 265 patients were randomized, 106 to olme/amlo/rosu, 106 to olme/rosu and 53 to olme/amlo groups. Baseline characteristics among the three groups did not differ. The mean sitSBP change was significantly larger in the olme/amlo/rosu group with −24.30 ± 12.62 mmHg (from 153.58 ± 10.90 to 129.28 ± 13.58) as compared to the olme/rosu group, −9.72 ± 16.27 mmHg (from 153.71 ± 11.10 to 144.00 ± 18.44 mmHg). The difference in change of sitSBP between the two groups was −14.62± 1.98 mmHg with significance (95% CI −18.51 to −10.73, p < 0.0001). The mean LDL-C reduced significantly in the olme/amlo/rosu group, −52.31 ± 16.63% (from 154.52 ± 30.84 to 72.72 ± 26.08 mg/dL) as compared to the olme/amlo group with no change, −2.98 ± 16.16% (from 160.42 ± 32.05 to 153.81 ± 31.57 mg/dL). Significant difference in change was found in LDL-C between the two groups with −50.10 ± 2.73% (95% CI −55.49 to −44.71, p < 0.0001). Total adverse drug reaction rates were 10.48%, 5.66% and 3.7% in the olme/amlo/rosu, olme/rosu and olme/amlo groups, respectively with no statistical significance among the three groups. Serious adverse drug reactions did not occur. Conclusions: Olmesartan/amlodipine single pill plus rosuvastatin combination treatment for patients with both hypertension and dyslipidemia is effective and safe as compared to either olmesartan plus rosuvastatin or olmesartan plus amlodipine treatment. MDPI 2022-01-11 /pmc/articles/PMC8779537/ /pubmed/35054044 http://dx.doi.org/10.3390/jcm11020350 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jo, Sang-Ho Kang, Seok Min Yoo, Byung Su Lee, Young Soo Youn, Ho Joong Min, Kyungwan Yu, Jae Myung Yoon, Hyun Ju Kim, Woo Shik Kim, Gee Hee Park, Jae Hyoung Kim, Seok Yeon Kim, Cheol Ho A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study |
title | A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study |
title_full | A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study |
title_fullStr | A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study |
title_full_unstemmed | A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study |
title_short | A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study |
title_sort | prospective randomized, double-blind, multi-center, phase iii clinical trial evaluating the efficacy and safety of olmesartan/amlodipine plus rosuvastatin combination treatment in patients with concomitant hypertension and dyslipidemia: a leisure study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779537/ https://www.ncbi.nlm.nih.gov/pubmed/35054044 http://dx.doi.org/10.3390/jcm11020350 |
work_keys_str_mv | AT josangho aprospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT kangseokmin aprospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT yoobyungsu aprospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT leeyoungsoo aprospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT younhojoong aprospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT minkyungwan aprospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT yujaemyung aprospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT yoonhyunju aprospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT kimwooshik aprospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT kimgeehee aprospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT parkjaehyoung aprospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT kimseokyeon aprospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT kimcheolho aprospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT josangho prospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT kangseokmin prospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT yoobyungsu prospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT leeyoungsoo prospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT younhojoong prospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT minkyungwan prospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT yujaemyung prospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT yoonhyunju prospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT kimwooshik prospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT kimgeehee prospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT parkjaehyoung prospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT kimseokyeon prospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy AT kimcheolho prospectiverandomizeddoubleblindmulticenterphaseiiiclinicaltrialevaluatingtheefficacyandsafetyofolmesartanamlodipineplusrosuvastatincombinationtreatmentinpatientswithconcomitanthypertensionanddyslipidemiaaleisurestudy |